Abundance of iron drives cell death and could inform novel treatments for neuroblastoma

Neuroblastoma is a cancer that develops in nerve tissue, most commonly in the glands around the kidneys. The gene MYCN is overexpressed in 20-25% of neuroblastoma, and MYCN-amplified neuroblastoma contributes to a considerable percentage of pediatric cancer-related deaths.

Anthony Faber, Ph.D., and a team of researchers at VCU Massey Cancer Center were awarded a grant from the American Cancer Society to study how MYCN and an abundance of iron can drive cancer cell death in neuroblastoma and potentially be targeted with novel treatments. This award is the first part of a potential two-stage grant worth a combined total of $600,000.

“Iron is a double-edged sword in a cancer cell. It can help the cancer grow and survive, but it also creates these toxic molecules within the cell called reactive oxygen species,” said Faber, Natalie N. and John R. Congdon Chair in Cancer Research and co-leader of the Developmental Therapeutics research program at Massey and associate professor in the Philips Institute for Oral Health Research at the VCU School of Dentistry.

Reactive oxygen species (ROS) are highly unstable chemical molecules that react with other molecules within a cell and cause damage to genes and cell death (ferroptosis). Ferroptosis is a recently discovered type of cell death that is largely influenced by the accumulation of iron. Faber said there is a relatively small scientific understanding of ferroptosis, and even less is known about which cancers may be prone to ferroptosis-inducing drugs.

Through recent research published in Cancer Research, Faber and his collaborators have determined that the MYCN gene creates a vulnerability to drugs that induce ferroptosis because MYCN uses a lot of iron to help power the cancer cell and grow uncontrollably.

By ramping up the systems that remove toxins on a cellular level, MYCN generates so much iron that it also initiates a weakness to drugs that block the ability of the cell to eliminate ROS, as discovered by Konstantinos Floros, Ph.D., postdoctoral fellow at Massey and the Philips Institute for Oral Health Research whose extensive background in cell death effectively advanced this research project.

The researchers found that blocking these detoxifying systems with available drugs makes MYCN-amplified cells sick and die.

“As MYCN continues to be one of the most important targets in cancer therapeutics, this study highlights a new and clinically important strategy for treating MYCN-associated cancers,” Faber said.

Using preclinical tumor models, Faber’s team will use the grant funding to test the ability of sulfasalazine and auronofin—drugs FDA-approved for rheumatoid arthritis—to induce ferroptosis and tumor responses in neuroblastoma cells with high levels of MYCN.

“Fortunately, the Cancer Mouse Models Core run by Jennifer Koblinski, Ph.D., and Bin Hu, Ph.D., at Massey is spectacular and will allow us to robustly test these FDA-approved drugs in both patient-derived models and orthotopic models, where the tumors grow atop the adrenal glands similar to the way they grow in patients,” Faber said.

Faber said that if they show positive results testing these drugs in cancer models, then they can confidently test these therapies in clinical trials.

Source: Read Full Article